title: Temporary deterioration of pulmonary functions after injection sclerotherapy for cirrhotic patients with esophageal varices.
abstract: In 34 cirrhotic patients with esophageal varices, a significant but temporary deterioration in pulmonary function tests occurred 24 h after endoscopic injection sclerotherapy using 5% ethanolamine oleate. Included were vital capacity, forced expiratory volume in 1 s, closing volume/vital capacity and arterial oxygen content. Twenty-four hours after the sclerotherapy, the patients complaining of postinjection retrosternal pain had a larger fall in vital capacity and forced expiratory volume in 1 s than did the patients without pain. Before the injection sclerotherapy, 11 of 34 patients had an arterial hypoxemia (PaO2 less than 80 mm Hg). In these patients, there was a significantly (p less than 0.001) higher value of closing volume before sclerotherapy and there were larger changes in both closing volume (p less than 0.01) and arterial oxygen content (p less than 0.01) 24 h after the injection sclerotherapy than in the patients without hypoxemia. Reversion to a state before sclerotherapy was attained 7 days after the sclerotherapy. Thus, patients undergoing sclerotherapy for bleeding esophageal varices should be closely monitored with regard to pulmonary function.
authors.affiliation: Department of Surgery II, Kyushu University Faculty of Medicine, Fukuoka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kitano
authors.forename: Y
authors.initials: Y
authors.lastname: Iso
authors.forename: H
authors.initials: H
authors.lastname: Yamaga
authors.forename: M
authors.initials: M
authors.lastname: Hashizume
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D000328:Adult; D004932:Esophageal and Gastric Varices / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D000860:Hypoxia / Q000150:complications; D008103:Liver Cirrhosis / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D008168:Lung / Q000503:physiopathology*; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D010996:Pleural Effusion / Q000000981:diagnostic imaging / Q000209:etiology; D013902:Radiography, Thoracic; D012129:Respiratory Function Tests; D012597:Sclerosing Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D012597:Sclerosing Solutions